Association of the COMT Met(158) allele with trait impulsivity in healthy young adults

Imagem de Miniatura
Arquivos
art_SOEIRO-DE-SOUZA_Association_of_the_COMT_Met(158)_allele_with_trait_2013.PDF (308.76 KB)
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
STANFORD, Matthew S.
Citação
MOLECULAR MEDICINE REPORTS, v.7, n.4, p.1067-1072, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Dopamine (DA) is considered to be an important neurotransmitter in the control of impulsive behavior, however, its underlying mechanisms have not been fully elucidated. Catechol-O-methyltransferase (COMT) is a key enzyme in the catabolism of DA within the prefrontal cortex (PFC) and has been suggested to play a role in the mediation of impulsive behavior. The COMT single nucleotide polymorphism (SNP) rs4680 (Val(158)Met) Met allele has been shown to decrease COMT enzyme activity and is associated with improved PFC cognitive function (intelligence and executive functions). Studies have associated the rs4680 genotype with impulsivity as a symptom in attention deficit hyperactivity disorder and substance abuse. However, only a few studies have assessed the effects of rs4680 on impulsiveness in healthy subjects, the results of which remain controversial. The Barratt Impulsiveness Scale (BIS-11) was applied to 82 healthy volunteers (including 42 females) who were genotyped for COMT rs4680. Subjects carrying the Met/Met genotype scored higher for the BIS-11 second-order factor Non-planning than carriers of the Val/Val genotype. No interaction between gender*genotype was detected. Age, gender and education had no effect on the results. The COMT rs4680 Met/Met genotype was associated with higher impulsivity on the BIS-11 second-order factor Non-planning. These results suggest that COMT enzyme activity may be important in the regulation of impulsiveness among young adults. Further studies involving larger samples should be conducted to confirm the results of the present study.
Palavras-chave
impulsivity, dopamine
URI
https://observatorio.fm.usp.br/handle/OPI/4619
Referências
  1. Alsene K, 2003, NEUROPSYCHOPHARMACOL, V28, P1694, DOI 10.1038/sj.npp.1300232
  2. Baca-Garcia E, 2005, PROG NEURO-PSYCHOPH, V29, P713, DOI 10.1016/j.pnpbp.2005.04.019
  3. Biederman J, 2008, AM J MED GENET B, V147B, P1511, DOI 10.1002/ajmg.b.30874
  4. Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542
  5. Bjork JM, 2002, AM J MED GENET, V114, P336, DOI 10.1002/ajmg.10206
  6. Boettiger CA, 2007, J NEUROSCI, V27, P14383, DOI 10.1523/JNEUROSCI.2551-07.2007
  7. Bruder GE, 2005, BIOL PSYCHIAT, V58, P901, DOI 10.1016/j.biopsych.2005.05.010
  8. Buckholtz JW, 2010, SCIENCE, V329, P532, DOI 10.1126/science.1185778
  9. Chen X, 2004, MOL PSYCHIATR, V9, P962, DOI 10.1038/sj.mp.4001519
  10. Colzato LS, 2010, NEUROSCIENCE, V170, P782, DOI 10.1016/j.neuroscience.2010.07.050
  11. Comings DE, 1997, MOL PSYCHIATR, V2, P44, DOI 10.1038/sj.mp.4000207
  12. Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9
  13. Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073
  14. Dang DE, 2011, CLIN NEUROPHARMACOL, V34, P66, DOI 10.1097/WNF.0b013e31820d6699
  15. de Lara CL, 2007, BIOL PSYCHIAT, V62, P72, DOI 10.1016/j.biopsych.2006.09.008
  16. DeYoung CG, 2010, PSYCHIAT GENET, V20, P20, DOI 10.1097/YPG.0b013e32833511e4
  17. Diamond A, 2004, AM J PSYCHIAT, V161, P125, DOI 10.1176/appi.ajp.161.1.125
  18. Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598
  19. Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481
  20. Forbes EE, 2009, MOL PSYCHIATR, V14, P60, DOI 10.1038/sj.mp.4002086
  21. Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991
  22. Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889
  23. Goldman-Rakic PS, 2004, PSYCHOPHARMACOLOGY, V174, P3, DOI 10.1007/s00213-004-1793-y
  24. Green L, 1999, J EXP PSYCHOL LEARN, V25, P418, DOI 10.1037/0278-7393.25.2.418
  25. Han DH, 2006, NEUROREPORT, V17, P95, DOI 10.1097/01.wnr.0000192740.38653.91
  26. Han DH, 2004, PSYCHIAT RES, V129, P29, DOI 10.1016/j.psychres.2004.06.013
  27. Hinson JM, 2003, J EXP PSYCHOL LEARN, V29, P298, DOI 10.1037/0278-7393.29.2.298
  28. Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483
  29. Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662
  30. Kim S, 2011, BIOL PSYCHIAT, V69, P1140, DOI 10.1016/j.biopsych.2010.07.005
  31. Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032
  32. Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007
  33. Lachman HM, 1996, AM J MED GENET, V67, P468, DOI 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G
  34. LAITINEN J, 1994, BIOTECHNIQUES, V17, P316
  35. Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652
  36. Mehta MA, 2000, J NEUROSCI, V20
  37. Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121
  38. Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783
  39. Nedic G, 2011, INT J NEUROPSYCHOPH, V14, P377, DOI 10.1017/S1461145710001057
  40. Nolan KA, 2011, PSYCHIAT RES, V187, P301, DOI 10.1016/j.psychres.2010.10.032
  41. O'Sullivan SS, 2009, CNS DRUGS, V23, P157, DOI 10.2165/00023210-200923020-00005
  42. Paaver M, 2007, PSYCHOPHARMACOLOGY, V194, P545, DOI 10.1007/s00213-007-0867-z
  43. Paloyelis Y, 2010, NEUROPSYCHOPHARMACOL, V35, P2414, DOI 10.1038/npp.2010.124
  44. Passamonti L, 2006, BIOL PSYCHIAT, V59, P334, DOI 10.1016/j.biopsych.2005.07.027
  45. Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
  46. Robert G, 2009, MOVEMENT DISORD, V24, P2316, DOI 10.1002/mds.22836
  47. Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025
  48. Sakado K, 2003, AM J MED GENET B, V121B, P71, DOI 10.1002/ajmg.b.20063
  49. Sequeira A, 2004, PSYCHIAT RES, V125, P87, DOI 10.1016/j.psychres.2003.12.002
  50. Sheehan DV, J CLIN PSYCHIAT S20, V59, P22
  51. Soeiro-de-Souza MG, 2012, BIPOLAR DISORD, V14, P554, DOI 10.1111/j.1399-5618.2012.01030.x
  52. Soeiro-de-Souza MG, 2012, J AFFECT DISORDERS, V136, P370, DOI 10.1016/j.jad.2011.11.021
  53. Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008
  54. St Onge JR, 2009, NEUROPSYCHOPHARMACOL, V34, P681, DOI 10.1038/npp.2008.121
  55. Swann AC, 2001, PSYCHIAT RES, V101, P195, DOI 10.1016/S0165-1781(00)00249-3
  56. Swann AC, 2002, BIOL PSYCHIAT, V51, P988, DOI 10.1016/S0006-3223(01)01357-9
  57. Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19
  58. Whitney P, 2004, PERS INDIV DIFFER, V37, P417, DOI 10.1016/j.paid.2003.09.013
  59. Williams-Gray CH, 2007, J NEUROSCI, V27, P4832, DOI 10.1523/JNEUROSCI.0774-07.2007
  60. Winstanley CA, 2006, CLIN PSYCHOL REV, V26, P379, DOI 10.1016/j.cpr.2006.01.001
  61. Zouk H, 2007, AM J MED GENET B, V144B, P996, DOI 10.1002/ajmg.b.30521

Coleções
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - ODS/03